Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. | The company’s cobas ...
HIV, the incurable virus that can lead to AIDS if not treated, is most prevalent in Georgia, with 23.1 cases per 100,000 ...
SCHD said that the partnership will allow expanded clinical services, enabling the health department to provide HIF and ...
The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...
A new strain of gonorrhea has emerged, causing significant concern among health professionals due to its resistance to traditional treatments. This sexually ...
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old ...
The World Health Organization (WHO) recently released new estimates suggesting around 846 million people aged between 15 and ...
US FDA grants 510(k) clearance and CLIA waiver to Roche’s cobas liat sexually transmitted infection multiplex assay panels: Basel Thursday, January 23, 2025, 09:00 Hrs [IST] Roc ...
The FDA granted clearance with a CLIA waiver for the cobas liat sexually transmitted infection (STI) assay, Roche announced; ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver ...
HPV can cause a variety of cancers, including cervical. New mortality data for women under 25 point to the success of the HPV vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback